NCT05192304View on ClinicalTrials.gov

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

PHASE1UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2024

Conditions
Schizophrenia
Interventions
DRUG

TPN-672

single dose of TPN-672 maleate tablet

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Mental Health Center

OTHER

lead

Jiangsu Kanion Pharmaceutical Co., Ltd

INDUSTRY

NCT05192304 - Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter